Alexandria Real Estate Equities, Inc.'s Consequential Efforts to Address the Mission-Critical Need for Multifaceted Solutions to the Nation's Complex Mental Health Crisis

PASADENA, Calif., May 27, 2025 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), the first, preeminent, longest-tenured and pioneering owner, operator and developer of collaborative Megacampus^™ ecosystems in AAA life science innovation cluster locations, continues to leverage its leadership position at the vanguard of the life science ecosystem to forge and strengthen strategic partnerships aimed at speeding and improving patient outcomes amid the nation's complex mental health crisis. As Mental Health Awareness Month 2025 comes to a close, Alexandria remains committed to its multipronged approach to advancing solutions: (1) investing in innovative new companies that are diagnosing and developing treatments and cures for neuropsychiatric disorders, (2) advancing an innovative public-private partnership to develop biomarkers to identify factors that influence treatment outcomes for depression, (3) influencing policy to accelerate innovation that saves lives and (4) partnering with non-profits such as the Navy SEAL Foundation to directly support individuals suffering from mental health conditions.

"We are immensely proud of the positive impact and potential of our ongoing endeavors to address our country's staggering mental health crisis. As part of our latest effort, we continue to spearhead the development of a public-private partnership with the Foundation for the National Institutes of Health (FNIH) and leading-edge medicine companies, with the goal of transforming how depression is understood, diagnosed and treated — essentially, laying the groundwork for a new era of precision psychiatry," said Joel S. Marcus, executive chairman and founder of Alexandria Real Estate Equities, Inc. and Alexandria Venture Investments. "In observance of Mental Health Awareness Month this May, we call for a national public health agenda that prioritizes and spurs innovation in our great country. And we urge continued investment in neuropsychiatric research by the NIH and a well-resourced FDA with efficient and streamlined approval processes for critical diagnostics and therapeutics."

With studies predicting that by 2030 the global economic burden of mental health disorders will surpass that of cancer, diabetes and respiratory diseases, progress in advancing novel medicines for neuropsychiatry is seeing a renaissance. Recent advancements include a first-in-class FDA-approved schizophrenia therapy developed by Karuna Therapeutics, a former Alexandria venture investment company and a recent acquisition by longtime Alexandria tenant Bristol Myers Squibb. Also, in February, the FDA accepted a supplemental new drug application for an adjunctive treatment for adults with major depressive disorder submitted by Alexandria tenant and former investment company Intra-Cellular Therapies, now part of Johnson & Johnson. If approved, this treatment has potential to become a new standard of care for most common depressive disorders.

The mission-critical FNIH public-private partnership aims to develop data-driven measures to identify patient populations that are most likely to meaningfully respond to innovative new treatments for depression. Recognizing that depression is not a single disease, but a complex disorder with a wide range of symptoms, severities and treatment responses, this program takes a precision psychiatry approach and leverages cross-sector expertise and advanced analytics to pave the way for more personalized, effective care tailored to a patient's unique needs.

For more than 15 years, Alexandria has also been partnering with the Navy SEAL Foundation to support its vital mission to provide the nation's elite warriors with physical and mental health resources. Most recently, Alexandria played an instrumental role in establishing and launching the foundation's Warrior Fitness Program West Coast facility in San Diego, which provides evidence-based support, advanced performance and fitness technology, and expert personnel to help Naval Special Warfare members recover physically and mentally. Since opening in late 2023, the facility has supported over 200 active-duty warriors and veterans. To learn more about the Navy SEAL Foundation Warrior Fitness Program, please visit navysealfoundation.org/programs/wfp/.

About Alexandria Real Estate Equities, Inc.

Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500^® company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. With our founding in 1994, Alexandria pioneered the life science real estate niche. Alexandria is the preeminent and longest-tenured owner, operator and developer of collaborative Megacampus^™ ecosystems in AAA life science innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle and New York City. As of March 31, 2025, Alexandria has a total market capitalization of $28.8 billion and an asset base in North America that includes 39.6 million RSF of operating properties and 4.0 million RSF of Class A/A+ properties undergoing construction. Alexandria has a longstanding and proven track record of developing Class A/A+ properties clustered in highly dynamic and collaborative Megacampus environments that enhance our tenants' ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity and success. Alexandria also provides strategic capital to transformative life science companies through our venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns and greater long-term asset value. For more information on Alexandria, please visit www.are.com.

Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, without limitation, statements regarding the impact of Alexandria's corporate responsibility and thought leadership initiatives, practices, investments and progress, the likelihood of continued support, investment and partnership by Alexandria and the potential impacts of such activities on Alexandria's business and tenants, the companies and non-profit organizations in which Alexandria invests or with which Alexandria has strategic relationships, medicines for mental health disorders and the country's mental health crises. These forward-looking statements are based on Alexandria's present intent, beliefs or expectations, but forward-looking statements are not guaranteed to occur and may not occur. Actual results may differ materially from those contained in or implied by Alexandria's forward-looking statements as a result of a variety of factors, including, without limitation, the risks and uncertainties detailed in its filings with the Securities and Exchange Commission. All forward-looking statements are made as of the date of this press release, and Alexandria assumes no obligation to update this information. For more discussion relating to risks and uncertainties that could cause actual results to differ materially from those anticipated in Alexandria's forward-looking statements, and risks and uncertainties to Alexandria's business in general, please refer to Alexandria's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and any subsequently filed quarterly reports on Form 10-Q. 

CONTACT: Sara Kabakoff, Senior Vice President – Chief Content Officer, (626) 788-5578, [email protected]  

SOURCE Alexandria Real Estate Equities, Inc.